Entering text into the input field will update the search result below

3 Things In Biotech, March 8: A Tale Of 3 New Trials

Mar. 09, 2018 8:00 AM ETALNAQ, DSKYF, SGEN2 Comments
Zach Hartman profile picture
Zach Hartman


  • Seattle Genetics steps into multiple myeloma with a phase 1 study.
  • Daiichi Sankyo gets rolling in phase 2 for HER2-positive colorectal cancer.
  • Allena Pharmaceuticals heads for the phase 3 goal in hyperoxaluria.

Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication.

Welcome to another edition of "3 Things In Biotech," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research.

Seattle Genetics steps into multiple myeloma with a phase 1 study

Company: Seattle Genetics (SGEN)

Therapy: SGN-CD48A

Disease: Relapsed/refractory multiple myeloma

News: SGEN announced that it initiated a phase 1 clinical study to assess the safety and tolerability of its CD48-directed antibody-drug conjugate SGN-CD48A in patients with relapsed/refractory multiple myeloma. The study will enroll 75 patients, and in addition to looking for a maximally tolerated dose, the company will evaluate antitumor activity.

Looking forward: Interesting approach getting underway from a proven leader in antibody-drug conjugate development. Hopefully, SGEN's efforts will pay off better than its other programs in recent years, as it still needs to find a new treatment option if it's to build on the success it has realized from marketing of brentuximab vedotin. For now, I don't personally know much about targeting CD48 in myeloma, so that approach is news to me, and I wouldn't want to offer too in-depth a comment on the prospect of this study.

However, this is still an interesting development, and I always welcome more ADC developments from SGEN.

Daiichi Sankyo gets rolling in phase 2 for HER2-positive colorectal cancer

Company: Daiichi Sankyo (OTCPK:DSKYF)

Therapy: DS-8201

Disease: HER2-positive advanced colorectal cancer

News: DSKYF has initiated a global phase 2 investigating the anti-HER2 antibody-drug conjugate DS-8201 in patients with HER2-positive colorectal cancer. This study will enroll patients who have received at least two prior lines of standard therapy, with a primary endpoint of overall response rate. Unsurprisingly, given the relatively heavily pretreated patient population, there is no placebo control.

Looking forward:

This article was written by

Zach Hartman profile picture
I am a former PhD scientist-turned-writer focused on cancer education. My writings in Seeking Alpha have been devoted to helping people identify promising investment opportunities in cancer research through commentary of recent events. Readers can learn more about other aspects of cancer research by visiting my site Invest Against Cancer.I also collaborate with Avisol Capital Partners on their Marketplace service known as the Total Pharma Tracker (TPT). Some of my work will be available to TPT subscribers either exclusively, or in advance. If you are interested, please click the link above!

Analyst’s Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.

Recommended For You

Comments (2)


More on CD48:

Br J Haematol. 2012 Jan;156(2):213-24. doi: 10.1111/j.1365-2141.20... Epub 2011 Nov 21.
CD48 as a novel molecular target for antibody therapy in multiple myeloma.

and at:
Zach Hartman profile picture
Thank you, Rancherho!
Disagree with this article? Submit your own. To report a factual error in this article, . Your feedback matters to us!
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.